Depo-Provera Lawsuit 2026: Meningioma Claims, MDL Status and Settlement Information
Depo-Provera lawsuits allege that repeated medroxyprogesterone acetate injections were associated with intracranial meningioma and that adequate warnings were not provided during relevant periods.
Federal cases are centralized in MDL 3140 in the Northern District of Florida. A potential claim may warrant review when documented use occurred before a confirmed meningioma diagnosis.
See Whether Your Depo-Provera Claim May Qualify
Complete the short form for a confidential review of your injection history, meningioma diagnosis, treatment, symptoms, and potential damages.
What Is the Depo-Provera Lawsuit About?
Depo-Provera is an injectable contraceptive containing medroxyprogesterone acetate. Plaintiffs allege that repeated use was associated with the development of intracranial meningioma and that warnings provided during relevant periods were inadequate. The defendants dispute liability and may challenge causation, warning theories, product identification, timing, and other elements of individual claims.
The federal litigation is not a class action that automatically pays everyone the same amount. Each plaintiff must prove product use, injury, causation, damages, and compliance with applicable deadlines. MDL centralization coordinates common pretrial issues while preserving individual case differences.
Who May Qualify for a Depo-Provera Lawsuit?
Screening standards can change as the litigation develops. A case may warrant review when several of the following facts are present:
- Documented use of Depo-Provera or another relevant depot medroxyprogesterone acetate injection.
- Repeated or prolonged injections before the diagnosis.
- A confirmed intracranial meningioma diagnosis.
- Treatment such as craniotomy, radiation, medication, rehabilitation, or continuing surveillance.
- Neurological symptoms, disability, lost income, medical expenses, or reduced quality of life.
- A filing deadline that has not expired under the law that applies to the claim.
A minimum-use threshold should not be presented as universal without a current law-firm or court screening standard. Records and individualized facts should be reviewed before stating that someone qualifies.
Depo-Provera MDL 3140 Status and Timeline
The Judicial Panel on Multidistrict Litigation centralized federal Depo-Provera products-liability cases in the Northern District of Florida on February 7, 2025. The litigation is assigned to Judge M. Casey Rodgers under master docket number 3:25-md-3140.
March 2024 — BMJ Study
The national case-control study reported an association between prolonged injectable medroxyprogesterone acetate use and intracranial meningioma requiring surgery.
February 2025 — MDL Centralization
JPML transferred federal cases to the Northern District of Florida for coordinated pretrial proceedings.
December 2025 — FDA Label Update
The FDA approved meningioma risk language in the U.S. prescribing information.
2026 — Active Pretrial Litigation
The court continues to manage common discovery, expert, threshold-proof, and other pretrial issues. Court orders—not marketing estimates—are the best source for current procedural status.
Depo-Provera Lawsuit Settlement Amounts in 2026
No global Depo-Provera settlement has been announced. Any dollar ranges discussed online are projections—not confirmed averages or guaranteed payouts. Potential value may depend on tumor grade and location, surgery, radiation, permanent deficits, recurrence, future treatment, age, wage loss, caregiving needs, product-use proof, causation evidence, jurisdiction, and litigation outcomes.
| Educational Claim Tier | Common Characteristics | Important Value Factors |
|---|---|---|
| Severe injury review | Craniotomy, recurrence, major neurological deficit, substantial disability, or wrongful death. | Surgery, pathology, permanent impairment, future care, earning loss, dependency, and strong use proof. |
| Moderate-to-severe review | Radiation, meaningful symptoms, substantial treatment, work limitations, or continuing neurological care. | Treatment burden, symptoms, medical expenses, wage loss, prognosis, and functional impact. |
| Monitoring or lower-damage review | Confirmed meningioma managed through surveillance, limited symptoms, or no invasive treatment to date. | Tumor size and location, monitoring burden, symptoms, future risk, and strength of causation evidence. |
What Does the Research Say About Depo-Provera and Meningioma?
A 2024 national case-control study published in The BMJ reported an association between prolonged use of injectable medroxyprogesterone acetate and intracranial meningioma requiring surgery. The reported odds ratio for prolonged injectable use was approximately 5.6. Because the study was observational, it identified an association and did not establish that Depo-Provera caused every tumor.
Later research has continued to evaluate the relationship between depot medroxyprogesterone acetate and meningioma. Individual causation still requires review of exposure duration, timing, competing risk factors, imaging, pathology, treatment, and expert evidence.
Documented Injection History
Pharmacy records, clinic notes, OB/GYN records, and administration logs may help establish product use and duration.
Confirmed Meningioma
MRI, CT, operative notes, pathology, radiation records, and neurosurgical reports may establish the injury and treatment.
Use Before Diagnosis
The sequence and duration of Depo-Provera use relative to tumor detection are central to an individualized review.
FDA Depo-Provera Meningioma Label Update
In December 2025, the FDA approved revised prescribing information adding meningioma risk language to the warnings and precautions for Depo-Provera CI and depo-subQ provera 104. The current label states that meningioma cases have been reported after repeated administration, primarily with long-term use, and directs clinicians to discontinue the product when meningioma is diagnosed.
Accuracy note: The meningioma language appears in the warnings and precautions section. It is not the subject of the product’s boxed warning; the boxed warning addresses loss of bone mineral density.
What Is a Meningioma?
A meningioma develops from the meninges, the membranes surrounding the brain and spinal cord. Many meningiomas are histologically benign, but their location and size may still cause serious neurological problems or require major treatment.
Possible Symptoms
Headaches, seizures, vision or hearing changes, weakness, memory problems, balance issues, or personality changes.
Diagnosis
MRI and CT imaging are commonly used. Pathology may confirm tumor type and grade after surgery.
Treatment
Monitoring, surgery, radiation, medication, rehabilitation, or a combination may be recommended depending on the tumor.
Long-Term Impact
Some patients experience recurrence, neurological deficits, reduced earning ability, ongoing surveillance, or future-care needs.
Evidence Commonly Reviewed in a Depo-Provera Claim
Proof of Use
Pharmacy records, injection logs, clinic records, insurance claims, Planned Parenthood records, OB/GYN records, and prescribing-provider notes.
Medical Evidence
MRI and CT reports, pathology, operative notes, radiation records, neurology and neurosurgery notes, medications, and rehabilitation records.
Damages Evidence
Medical bills, wage records, disability documentation, travel expenses, caregiving costs, symptom journals, and evidence of daily-life limitations.
How a Depo-Provera Lawsuit May Be Evaluated and Filed
- Initial screening: Review product use, diagnosis, treatment, dates, jurisdiction, and possible deadlines.
- Record collection: Obtain injection, pharmacy, imaging, pathology, surgery, radiation, wage, and damages records.
- Legal and medical review: Evaluate product identification, causation, warning issues, damages, and applicable law.
- Complaint and case administration: A retained attorney may file an individual lawsuit and comply with MDL requirements when appropriate.
- Discovery and expert issues: The parties exchange evidence and litigate common and case-specific issues.
- Resolution: A claim may be dismissed, settled, remanded, or tried. No particular outcome is guaranteed.
Depo-Provera Lawsuit Filing Deadlines
Statutes of limitations vary by state and may depend on diagnosis, discovery of a possible connection, product use, residence, prescription location, defendant conduct, minority, incapacity, wrongful death, and other facts. A generic “two-to-four-year” statement is not reliable for every person.
Because a missed deadline may permanently bar a claim, obtain a state-specific review promptly. Do not wait for a bellwether trial or a possible settlement announcement before investigating a deadline.
Depo-Provera Lawsuit FAQ
Is there a Depo-Provera class action lawsuit?
Federal cases are coordinated in MDL 3140, not a traditional class action paying every claimant the same amount. Plaintiffs retain individual claims and must establish their own use, injury, causation, damages, and deadlines.
Has the Depo-Provera lawsuit settled?
No global settlement has been announced. Published dollar ranges are educational projections, not confirmed averages or guaranteed awards.
What diagnosis is central to the litigation?
The federal litigation principally concerns intracranial meningioma allegations following depot medroxyprogesterone acetate use.
How much could a Depo-Provera claim be worth?
Potential value depends on treatment, surgery, neurological deficits, recurrence, future care, wage loss, age, proof of use, causation evidence, jurisdiction, and litigation outcomes.
What records help prove Depo-Provera use?
Pharmacy claims, clinic injection logs, OB/GYN records, Planned Parenthood records, insurance records, and prescribing-provider notes may help establish use.
Should someone stop Depo-Provera without medical advice?
No. Contraceptive and treatment decisions should be discussed with a licensed healthcare professional. The current FDA label directs discontinuation if meningioma is diagnosed.
What if the injections came from a clinic?
Clinic and provider records may be important proof of use. A products-liability claim typically focuses on manufacturer-related allegations, but the proper defendants and theories depend on the facts and law.
How quickly should a potential claim be reviewed?
Promptly. Filing deadlines vary and may depend on state-specific discovery rules and individual facts. Waiting for a settlement announcement can create deadline risk.
Primary Sources and External References
Sources should support the statement nearest to them. Litigation status can change, so court orders and official agency documents should be checked before publishing exact procedural claims or case counts.
- U.S. District Court for the Northern District of Florida — Depo-Provera MDL 3140. Official litigation page and master-docket information. Accessed June 29, 2026.
- Judicial Panel on Multidistrict Litigation — MDL 3140 Transfer Order. Official February 7, 2025 centralization order. Accessed June 29, 2026.
- FDA-approved Depo-Provera CI and depo-subQ provera 104 prescribing information. Includes current meningioma warnings and precautions. Accessed June 29, 2026.
- FDA supplement approval letter dated December 12, 2025. Describes approval of meningioma risk information. Accessed June 29, 2026.
- Roland N, et al. Use of progestogens and the risk of intracranial meningioma. The BMJ, 2024. Accessed June 29, 2026.
- PubMed record for the 2024 national case-control study. Bibliographic and study abstract information. Accessed June 29, 2026.
Request a Confidential Depo-Provera Case Review
Use the form above or call to discuss your injection history, meningioma diagnosis, treatment, evidence, deadlines, and possible legal options.
